M0324
/ EMD Serono
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 21, 2025
TITER: M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=77 | Recruiting | Sponsor: EMD Serono Research & Development Institute, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • IO biomarker • Monotherapy • Solid Tumor
September 11, 2025
TITER: M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=77 | Not yet recruiting | Sponsor: EMD Serono Research & Development Institute, Inc.
IO biomarker • Monotherapy • New P1 trial • Solid Tumor
March 26, 2025
M0324, a novel MUC-1 conditional CD40 agonist for selective immune activation in MUC-1 overexpressing tumors
(AACR 2025)
- "M0324 is the first MUC-1 conditional CD40 agonist, engineered to selectively activate immune cells in the presence of MUC-1 overexpressing tumor cells. The conditional mode of action of M0324 leverages the high expression of MUC-1 in carcinomas to induce targeted antitumor immunity, potentially overcoming the safety limitations of traditional CD40 agonists. Our encouraging preclinical data support the clinical investigation of M0324 in patients with MUC-1 overexpressing tumors."
IO biomarker • Oncology • CD40 • MUC1
1 to 3
Of
3
Go to page
1